Medical Condition News

RSS

Probiotic drink changes reaction of cells lining nasal passages of hay fever sufferers

A study has shown that a daily probiotic drink changed how cells lining the nasal passages of hay fever sufferers reacted to a single out-of-season challenge. However, it did not lead to significant changes in hay fever symptoms, although this challenge test may not have accurately represented natural allergen exposure.

27 Nov 2013

Advances in cardiovascular sciences to be discussed at University of Leicester

Advances in Cardiovascular Sciences are to be showcased in two public lectures at the University of Leicester.

27 Nov 2013

Implantable genetic circuit serves as early warning system for high blood-fat levels

Humankind has a weight problem - and not only in the industrialised nations, either: the growing prosperity in many Asian or Latin American countries goes hand in hand with a way of life that quite literally has hefty consequences.

27 Nov 2013

More nuts, more health benefits

In a large new study, observational researchers at Harvard University looked at how eating nuts may help reduce the risk of mortality, finding that those who ate nuts daily, such as pistachios, saw health benefits nearly double.

27 Nov 2013

Novel micro-catheter fluorescent dye method to treat aneurysm in deep brain

In March 2013, Eric Wagner told his wife to call 9-1-1 because he was feeling the worst that he had ever felt. He was rushed by EMS to University Hospitals (UH) Ahuja Medical Center, and then airlifted to UH Case Medical Center, where brain scans showed that he had a ruptured aneurysm, a leaking blister on a blood vessel that was letting blood flow into his brain and causing a stroke.

27 Nov 2013

Fluxion Biosciences reports first study results from early stage NSCLC patients

Fluxion Biosciences, Inc. announced the presentation of the first pilot study results aimed at isolating circulating tumor cells (CTCs) from early stage non-small cell lung cancer (NSCLC) patients obtained in collaboration with Dr. Max Diehn's lab at Stanford University. CTCs are cells that disseminate from primary tumors and contribute to the spread of the disease to other parts of the body.

From Fluxion Biosciences 27 Nov 2013

Smaller micropolitan areas of the U.S. have very few rheumatologists

A novel study published in the American College of Rheumatology journal, Arthritis & Rheumatism, shows that smaller micropolitan areas of the U.S.-those with less than 50,000 people-have very few or no practicing adult rheumatologist. In some of these areas, individuals have to travel more than 200 miles to reach the closest rheumatologist.

27 Nov 2013

Drug interactions impact use of cholesterol-lowering statin drugs

A new study has found that many people who stopped taking cholesterol-lowering statin drugs were also taking an average of three other drugs that interfered with the normal metabolism of the statins.

27 Nov 2013

EPCs: A promising therapy for type 1 diabetes

Pancreatic islet transplantation is a promising therapy for treating type 1 diabetes, but the majority of transplanted cells die soon after they are transplanted.

27 Nov 2013

UMass Medical School licenses "anti-gal" technology to Agalimmune

The University of Massachusetts Medical School has licensed "anti-gal" technology developed by Professor of Surgery and Medicine Uri Galili, PhD, to newly formed biopharmaceutical company Agalimmune Ltd. for the purpose of developing innovative immunotherapies for the treatment of solid tumor cancers. Agalimmune is supported by an investment group comprising Loxbridge Research LLP and Animatrix Capital LLP and is based in London and California.

27 Nov 2013

Protecting or boosting neurotrophins may slow progression of Huntington's disease

A drug that acts like a growth-promoting protein in the brain reduces degeneration and motor deficits associated with Huntington's disease in two mouse models of the disorder, according to a study appearing November 27 in the Journal of Neuroscience. The findings add to a growing body of evidence that protecting or boosting neurotrophins - the molecules that support the survival and function of nerve cells - may slow the progression of Huntington's disease and other neurodegenerative disorders.

27 Nov 2013

Treatments based on behavioral or non-invasive physiological stimulation show greatest potential

Because the concept of permanent neurological injury has given way to recognition of the brain's potential for long-term regeneration ad reorganization, rehabilitations strategies are undergoing radical changes. The potential for five new translational interventions was examined in an article published ahead of print on November 13 by Neurology Clinical Practice: Barrett AM, Oh-Park M, Chen P, Ifejika NL: Five New Things in Neurorehabilitation.

27 Nov 2013

Alcohol use disorders contribute more significantly to disease burden

Disorders related to the abuse of alcohol contribute significantly to the burden of disease in the U.S., finds a new study in Alcoholism: Clinical and Experimental Research. Researchers estimated that in 2005, about 53,000 men and 12,000 women died from issues related to alcohol use disorders.

27 Nov 2013

Study links genetic predisposition to childhood obesity

Research has suggested that a particular gene in the brain's reward system contributes to overeating and obesity in adults. This same variant has now been linked to childhood obesity and tasty food choices, particularly for girls, according to a new study by Dr. Patricia Silveira and Prof. Michael Meaney of McGill University and Dr. Robert Levitan of the University of Toronto.

27 Nov 2013

African Americans have double the risk of end-stage renal disease compared to white Americans

In the United States, African Americans have approximately twice the risk of end-stage renal disease compared to white Americans, despite a similar prevalence in earlier stages of chronic kidney disease. A large study co-authored by George Washington University researcher Dominic Raj, M.D., identifies factors that mediate differences in the progression of chronic kidney disease between black patients and white patients, as well as among black patients, in order to reduce the excess burden of end-stage renal disease and its complications in black patients.

27 Nov 2013

Survivors of hematopoietic stem cell transplant benefit from expressive helping

A new study finds that survivors of hematopoietic stem cell transplant, an aggressive treatment for blood cancers, benefited from a two-part peer support process the authors call expressive helping.

27 Nov 2013

Freiburg scientists discover substance that suppresses unchecked cell division in leukemia cells

Scientists of the University of Freiburg and the Freiburg University Medical Center from the collaborative research center Medical Epigenetics (SFB 992) have discovered a new active substance that inhibits cell division in leukemia cells and could play an important role in the fight against cancer.

27 Nov 2013

Women who test negative for family-specific BRCA2 mutations may have four times risk for breast cancer

Women who are members of families with BRCA2 mutations but who test negative for the family-specific BRCA2 mutations are still at greater risk for developing breast cancer compared with women in the general population, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

27 Nov 2013

CSHL identifies specific stretch of DNA that helps cancerous blood cells to proliferate in AML

A team of researchers at Cold Spring Harbor Laboratory (CSHL) has identified a leukemia-specific stretch of DNA called an enhancer element that enables cancerous blood cells to proliferate in Acute Myeloid Leukemia (AML), a devastating cancer that is incurable in 70% of patients.

27 Nov 2013

FDA accepts Purdue Pharma's Targiniq ER Tablets CII NDA for review

Purdue Pharma L.P. today announced that the U.S. Food and Drug Administration has accepted for review a New Drug Application for Targiniq ER (oxycodone HCl/naloxone HCl controlled-release) Tablets CII, for the management of chronic pain.

27 Nov 2013

Medical Condition News

Probiotic drink changes reaction of cells lining nasal passages of hay fever sufferers

Advances in cardiovascular sciences to be discussed at University of Leicester

Implantable genetic circuit serves as early warning system for high blood-fat levels

More nuts, more health benefits

Novel micro-catheter fluorescent dye method to treat aneurysm in deep brain

Fluxion Biosciences reports first study results from early stage NSCLC patients

Smaller micropolitan areas of the U.S. have very few rheumatologists

Drug interactions impact use of cholesterol-lowering statin drugs

EPCs: A promising therapy for type 1 diabetes

UMass Medical School licenses "anti-gal" technology to Agalimmune

Protecting or boosting neurotrophins may slow progression of Huntington's disease

Treatments based on behavioral or non-invasive physiological stimulation show greatest potential

Alcohol use disorders contribute more significantly to disease burden

Study links genetic predisposition to childhood obesity

African Americans have double the risk of end-stage renal disease compared to white Americans

Survivors of hematopoietic stem cell transplant benefit from expressive helping

Freiburg scientists discover substance that suppresses unchecked cell division in leukemia cells

Women who test negative for family-specific BRCA2 mutations may have four times risk for breast cancer

CSHL identifies specific stretch of DNA that helps cancerous blood cells to proliferate in AML

FDA accepts Purdue Pharma's Targiniq ER Tablets CII NDA for review

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News